Glaucoma is a form of eye disorder that
harms the optic nerve which carries information from the individual’s
eye to the brain. It generally occurs when fluid develops in the
anterior part of the eye. The extra fluid that is formed causes rise in
pressure, also known as the intraocular pressure (IOP), on the eye,
thereby damaging the nerve which can lead to vision loss. The disorder
is typically caused due to high fluid pressure in the eyes. Other less
common causes include severe eye infection, inflammatory conditions,
chemical or blunt injury to the eyes, and blocked blood vessels in the
eyes. The two major forms of glaucoma are open angle glaucoma and
angle-closure glaucoma. The former is the most common type of glaucoma
observed across the globe. Traditionally, laser incisional surgery (tube
shunts or trabeculectomy) and topical medications have been the
principal means to reduce IOP and treat glaucoma. High cost of
treatment, lower patient compliance, and risk due to complications have
shifted focus of the medical fraternity toward more effective and safe
methods for the treatment of glaucoma. Minimally invasive glaucoma
surgery (MIGS), which uses microscopic sized equipment and tiny
incisions is a promising alternative for the management of glaucoma over
other traditional treatment methods.
Report Overview @ https://www.transparencymarketresearch.com/minimally-invasive-glaucoma-surgery-devices-market.html
Rise in burden of glaucoma across the
globe is a major factor fueling the growth of the minimally invasive
glaucoma surgery (MIGS) devices market. According to World Health
Organization (WHO) 2010 report, glaucoma was the second largest cause of
blindness after cataract across the globe and caused blindness in 4.5
million people, which is around 12% of all global blindness. Cases of
glaucoma are expected to rise further due to increase in geriatric
population. This in turn is expected to drive demand for MIGS devices
required for corrective eye surgeries. Grant of regulatory approvals and
subsequent new product launches is a major factor driving the minimally
invasive glaucoma surgery (MIGS) devices market. In December 2017,
Glaukos Corporation announced that the U.S. Food and Drug Administration
(FDA) had approved its move to conduct U.S. Investigational Device
Exemption (IDE) clinical trial study of iStent SA Trabecular
Micro-Bypass System intended to be used as standalone procedure for the
treatment of patients affected by primary open angle glaucoma. In April
2017, Alcon announced the launch of CyPass Micro-Stent, an MIGS device
indicated in the treatment of primary open angle glaucoma in the
European Union (EU). The other factor contributing to the growth of the
market is increased effectiveness and safety associated with these
devices. MIGS procedures are comparatively safer than traditional tube
shunt surgeries and trabeculectomy, as these eliminate the complications
associated with the above surgeries such as bleb infection and low eye
pressure. Moreover, MIGS procedures have shorter surgery time which is
quite important for patient safety. However, high cost of treatment and
risks associated with ophthalmic surgery are the factors likely to
hamper the growth of the market.
The global minimally invasive glaucoma
surgery (MIGS) devices market can be segmented based on surgery type,
end-user, and region. In terms of surgery type, the market can be
divided into standalone glaucoma surgery, glaucoma in conjunction with
cataract surgery, and others. Based on end-user, the global minimally
invasive glaucoma surgery (MIGS) devices market can be classified into
hospitals, ambulatory surgical centers, and ophthalmology clinics.
Geographically, the global minimally
invasive glaucoma surgery (MIGS) devices market can be segmented into
North America, Europe, Asia Pacific, Latin America, and Middle East
& Africa. North America dominates the global market due to large
number of patients receiving eye surgeries for glaucoma as compared to
other regions. Additionally, government support in the form of surplus
funding for research & development activities in the field of
glaucoma surgical devices is anticipated to help the region continue its
dominance during the forecast period. North America was followed by
Europe and Asia Pacific. The market in Asia Pacific is anticipated to
grow at a rapid pace during the forecast period due to increase in
patient pool with glaucoma, rise in government expenditure on health
care, and measures adopted to eradicate blindness in their respective
countries.
Prominent players operating in the global
minimally invasive glaucoma surgery (MIGS) devices market are Alcon,
Inc., Ellex Medical Lasers Ltd., Glaukos Corporation, and Ivantis, Inc.,
among others.
No comments:
Post a Comment